Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.
Systematic Review and Critique of Health Economic Models on Relapsing-Remitting Multiple Sclerosis in the UK.
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.
Hippocampal expressions of metallothionein I/II and glycoprotein 96 in EAE-prone and EAE-resistant strains of rats.
Comparison of a Markov Cohort Model and a Discrete-Event Simulation for Economic Analyses of Treatments for Multiple Sclerosis.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor.
A fatal mycotic sepsis after retrograde intrarenal surgery: a case report and literature review.
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Chronic pain disrupts the reward circuitry in multiple sclerosis.
All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
Consent guidance: patients and doctors making decisions together
Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis.
Pharmacoeconomic Aspects of Multiple Sclerosis Treatments in Iran.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
CellCept (Product Insert)
Efficacy of hematopoietic stem cell formultiple sclerosis, an evidence based meta-analysis.
A Study of Efficacy and Safety of Ocrelizumab in Patients with Relapse-Remitting Multiple Sclerosis
A review of Neuropharmacology Effects of Nigella sativa and Its Main Component, Thymoquinone.
Factors Associated with Caregiver's Burden in Relapsing-Remitting Multiple Sclerosis and Satisfaction with Current Therapies. MS-Feeling Study.
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
25 Hydroxyvitamin D and Cytokines in Multiple Sclerosis.
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold